The RNAi Web
What is RNAi
RNAi Timeline
siRNA Design
RNAi Glossary
RNAi Web Resources
  ::RNAi Services
  ::RNAi News & Publications
  ::RNAi Conferences
  ::RNAi Companies
  ::RNAi Therapy & Clinical Trials
  ::RNAi Products
  ::RNAi Tools & Software
  ::siRNA Collections & Databases
  ::RNAi BBS & Mailing List
  ::RNAi Animations & Images
RNAi Books
:: Home :: Feedback ::  

RNAi Therapy & Clinical Trials

Sponsored Links
  • Alnylam Pharmaceuticals, Inc. 0.00 - Alnylam was founded by Nobel Laureate Phillip Sharp, Thomas Tuschl et al. The company's current capabilities are supporting the development of Direct RNAi™ therapeutics. These products are designed to be administered directly to sites of diseases in various parts of the body, such as the eye, the brain or the lungs.
  • Calando Pharmaceuticals 0.00 - Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics and develops nanoparticle therapeutics that use sugar (cyclodextrin)-based polymer technologies as a drug delivery system for siRNA. CALAA-01, the company's leading drug candidate for treating cancer, is in phase II trial.
  • Silence Therapeutics 0.00 - Silence Therapeutics has several RNAi drugs in phase I and II trials for treating diabetic macular edema, age-related macular degeneration, acute kidney injury, and cancers.
  • Sirna Therapeutics, Inc 0.00 - The company's researchers are developing siRNAs targeting the VEG-F (vascular endothelial growth factor) for the treatment of macular degeneration, the leading cause of blindness, and hepatitis C virus.

Home - Feedback
© 2004-2013 The RNAi Web, All rights reserved.